NP_003336.1
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
NCBI Official Full Name
SUMO-conjugating enzyme UBC9
NCBI Official Synonym Full Names
ubiquitin-conjugating enzyme E2I
NCBI Protein Information
SUMO-conjugating enzyme UBC9
UniProt Protein Name
SUMO-conjugating enzyme UBC9
UniProt Synonym Protein Names
SUMO-protein ligase; Ubiquitin carrier protein 9; Ubiquitin carrier protein I; Ubiquitin-conjugating enzyme E2 I; Ubiquitin-protein ligase I; p18
UniProt Synonym Gene Names
UniProt Entry Name
UBC9_HUMAN
NCBI Summary for UBE2I
The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of enzymes: ubiquitin-activating enzymes, or E1s, ubiquitin-conjugating enzymes, or E2s, and ubiquitin-protein ligases, or E3s. This gene encodes a member of the E2 ubiquitin-conjugating enzyme family. Four alternatively spliced transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Jul 2008]
UniProt Comments for UBE2I
UBC9: Accepts the ubiquitin-like proteins SUMO1, SUMO2, SUMO3 and SUMO4 from the UBLE1A-UBLE1B E1 complex and catalyzes their covalent attachment to other proteins with the help of an E3 ligase such as RANBP2 or CBX4. Can catalyze the formation of poly- SUMO chains. Necessary for sumoylation of FOXL2 and KAT5. Essential for nuclear architecture and chromosome segregation. Interacts with HIPK1, HIPK2, PPM1J, RASD2 and TCF3 Interacts with NR2C1; the interaction promotes its sumoylation. Forms a tight complex with RANGAP1 and RANBP2. Interacts with SIAH1 and PARP. Interacts with various transcription factors such as TFAP2A, TFAP2B, TFAP2C, AR, ETS1 and SOX4. Interacts with RWDD3; the interaction enhances the sumoylation of a number of proteins such as HIF1A and I-kappa-B. Interacts with DNMT1. Interacts with FOXL2. Forms a complex with SENP6 and UBE2I in response to UV irradiation. Interacts with human herpesvirus 6 IE2. Interacts with human adenovirus early E1A protein; this interaction interferes with polysumoylation (Probable). Interacts with DNM1l (via its GTPase and B domains); the interaction promotes sumoylation of DNM1L, mainly in its B domain. Interacts with PML-RARA oncoprotein (via the coiled-colied domain); the interaction is required for sumoylation of the PML- RARA oncoprotein. Interacts with IPO13. Interacts with NFATC2IP; this inhibits formation of poly-SUMO chains. Expressed in heart, skeletal muscle, pancreas, kidney, liver, lung, placenta and brain. Also expressed in testis and thymus. Belongs to the ubiquitin-conjugating enzyme family.
Protein type: EC 6.3.2.-; Ubiquitin conjugating system; Ubiquitin ligase; Ligase; EC 6.3.2.19; SUMO conjugating system; Nuclear receptor co-regulator
Chromosomal Location of Human Ortholog: 16p13.3
Cellular Component: nucleoplasm; PML body; cytoplasm; dendrite; fibrillar center; synapse; synaptonemal complex; nucleus
Molecular Function: protein C-terminus binding; protein binding; enzyme binding; ubiquitin protein ligase binding; bHLH transcription factor binding; HLH domain binding; transcription factor binding; ATP binding; ligase activity
Biological Process: ubiquitin-dependent protein catabolic process; mitosis; proteasomal ubiquitin-dependent protein catabolic process; cellular protein metabolic process; protein sumoylation; viral reproduction; cell division; positive regulation of steroid hormone receptor signaling pathway; protein modification process; protein ubiquitination; positive regulation of transcription factor activity; negative regulation of transcription from RNA polymerase II promoter; regulation of receptor activity; post-translational protein modification; negative regulation of transcription, DNA-dependent; chromosome segregation
Product References and Citations for anti-UBE2I antibody
Expression analysis of Ubc9, the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in normal and malignant tissues. Moschos SJ, et al. Hum Pathol, 2010 Sep. PMID 20561671. Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner. Zhu S, et al. Oncogene, 2010 Mar 25. PMID 20023705. Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy. Han JY, et al. Pharmacogenomics J, 2010 Apr. PMID 19859084. Characterization of papillomavirus E1 helicase mutants defective for interaction with the SUMO-conjugating enzyme Ubc9. Fradet-Turcotte A, et al. Virology, 2009 Dec 20. PMID 19836047. Ubc9 gene polymorphisms and late-onset Alzheimer's disease in the Korean population: a genetic association study. Ahn K, et al. Neurosci Lett, 2009 Nov 20. PMID 19765634.
Research Articles on UBE2I
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with anti-UBE2I antibody
Diseases associated with anti-UBE2I antibody
Organs/Tissues associated with anti-UBE2I antibody
|